LAURUSLABS vs LINCOLN: Stock Comparison
LAURUS LABS is the larger company by market capitalisation. LAURUS LABS shows a higher ROE, a higher ROCE and a higher net margin, while LINCOLN PHARMA shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
LAURUSLABS leads 7; LINCOLN leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| Live Price | ₹2,002.5 | ₹510.85 |
| Day Change | -0.5% | -0.72% |
| Volume | 15.39 L | 61,149 |
| 52-Week High | ₹2,089 | ₹770 |
| 52-Week Low | ₹902.35 | ₹440 |
| Distance from 52W High | -4.14% | -33.66% |
Valuation
| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| Market Cap | ₹1.08 L Cr | ₹1,023 Cr |
| P/E Ratio | 98.67x | 10.61x |
| P/B Ratio | 20.35x | 1.35x |
| EPS | ₹6.8 | ₹18.09 |
| Book Value | ₹100.53 | ₹378.25 |
| Dividend Yield | 0.1% | 0.35% |
Growth
| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| Revenue Growth (TTM YoY) | 5.3% | 11.4% |
| EPS Growth (TTM YoY) | 19.4% | 0.6% |
| Qtr Sales Growth | 11.85% | 0% |
| Qtr Profit Growth | 28.35% | 0% |
Profitability & Leverage
| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| ROE | 16.39% | 11.6% |
| ROCE | 13.2% | 10.97% |
| Net Margin | 13.76% | 13.1% |
| Operating Margin | 19.85% | 17.38% |
| Debt to Equity | 0.44x | 0.01x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | LAURUSLABS | LINCOLN |
|---|---|---|
| Promoter Holding | 27.47%▼ 0.02 pp | 49.78% |
| FII Holding | 28%▲ 2.18 pp | 4.6%▼ 0.59 pp |
| DII Holding | 13.74%▼ 0.23 pp | 0.27%▼ 0.82 pp |
| Public Holding | 30.78%▼ 1.93 pp | 45.36%▲ 1.42 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: LAURUS LABS and LINCOLN PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.